Use of Red-Shifted Dyes in a Fluorescence Polarization AKT Kinase Assay for Detection of Biological Activity in Natural Product Extracts

Author:

Turek-Etienne Tammy C.1,Lei Ming1,Terracciano Joseph S.1,Langsdorf Erik F.1,Bryant Robert W.1,Hart Richard F.1,Horan Ann C.1

Affiliation:

1. Department of New Lead Discovery, Schering-Plough Research Institute, Kenilworth, NJ

Abstract

Kinases are an important therapeutic target for drug discovery, and many cancer chemotherapeutic agents have been derived from natural product sources. Natural product samples, however, have the likelihood of assay interference, particularly at elevated test concentrations. The authors developed a competitive fluorescence polarization (FP) assay using red-shifted fluorophores for the AKT kinase and demonstrated utility for testing concentrated natural product extracts. A set of 7 actinomycetes cultures containing indolocarbazoles, known nonselective kinase inhibitors, and a control set of 22 nonproducing indolocarbazole cultures were evaluated. Using red-shifted dyes (Cy3B™ or Cy5™), the authors identified active samples with minimal interference up to the extract concentrations that are 3 times nonextracted culture levels. In contrast, a significant number of interferences were observed using either a fluorescein competitive FP assay or a [33P]ATP Flashplate assay. This work demonstrates that one can screen natural product extracts at high concentrations successfully using FP technology with red-shifted dyes. ( Journal of Biomolecular Screening 2004:52-61)

Publisher

Elsevier BV

Reference39 articles.

1. 1. Fabbro D, Garcia-Echeverria C: Targeting protein kinases in cancer therapy . Curr Opin Drug Discov Dev 2002;5: 701-712 .

2. 2. Orchard S: Kinases as targets: prospects for chronic therapy . Curr Opin Drug Discov Dev 2002;5: 713-717 .

3. Tyrosine kinase inhibitors: From rational design to clinical trials

4. Imatinib mesylate (Gleevec(R)/Glivec(R)): A new therapy for chronic myeloid leukemia and other malignancies

5. 5. Zimmermann J: Glivec: a new treatment modality for CML: a case history . Chimia 2002;56: 428-431 .

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3